Additional Information

Description

Opdivo (nivolumab) 10 mg/mL 12 mL single-dose vial is an immune checkpoint inhibitor used in the treatment of various cancers, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, Hodgkin’s lymphoma, and other malignancies. It is a programmed death-1 (PD-1) receptor-blocking antibody that enhances T-cell activation and immune response against tumor cells.

The therapeutic effect of Opdivo is based on its ability to block the interaction between PD-1 and its ligands (PD-L1 and PD-L2), enabling cytotoxic T lymphocytes to recognize and attack cancer cells more effectively. It is administered as an intravenous infusion. The drug is often used as monotherapy or in combination with other immunotherapies or chemotherapeutic agents to improve treatment efficacy.

Common adverse effects include fatigue, rash, diarrhea, pruritus, and infusion-related reactions. Serious immune-mediated toxicities such as pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis may occur, requiring prompt medical intervention. Regular monitoring of liver enzymes, thyroid function, and renal parameters is necessary to detect early signs of toxicity.